Risks in a Trial of an Innovative Treatment of Duchenne Muscular Dystrophy

被引：2

作者：

Bos, Wendy ^{[1
]}

Westra, Anna E. ^{[2
]}

Pinxten, Wim ^{[3
]}

Mayer, Matthew P. ^{[4
]}

Lantos, John D. ^{[4
]}

机构：

[1] Erasmus Univ, Med Ctr, Dept Med Eth & Philosophy Med, Rotterdam, Netherlands

[2] Leiden Univ, Med Ctr, Dept Paediat, Leiden, Netherlands

[3] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium

[4] Childrens Mercy Hosp, 2401 Gillham Rd, Kansas City, MO 64105 USA

来源：

PEDIATRICS | 2015年 / 136卷 / 06期

关键词：

D O I：

10.1542/peds.2015-1589

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Studies of innovative therapies for muscular dystrophy raise unique ethical issues. The disease is currently untreatable and relentlessly progressive. A number of potentially efficacious treatments are being developed, but like all treatments, they may have unforeseen adverse effects. Nevertheless, patients and families, facing a bleak future, may be willing to take the gamble and try the treatments. Many doctors are eager to study them. But should institutional review boards approve them? This article discusses these issues and recounts the ways that one such study elicited different responses from different institutional review boards.

引用

页码：1173 / 1177

页数：5

共 50 条

[21] Duchenne muscular dystrophy: an important negative trial
Griggs, Robert C.
LANCET NEUROLOGY, 2010, 9 (11): : 1038 - 1039
[22] DECISION-MAKING AND EXPERIENCED BENEFITS AND RISKS OF CORTICOSTEROIDS AS A TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY
Porter, K.
Fischer, R.
Peay, H.
VALUE IN HEALTH, 2021, 24 : S143 - S143
[23] Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy
Shieh, Perry B.
NEUROTHERAPEUTICS, 2018, 15 (04) : 840 - 848
[24] Treatment of Duchenne muscular dystrophy at the mRNA level
Matsuo, M
Takeshima, Y
FRONTIERS IN HUMAN GENETICS: DISEASES AND TECHNOLOGIES, 2001, : 347 - 356
[25] Colonic distension treatment in Duchenne muscular dystrophy
Fiorentino, Giuseppe
Esquinas, Antonio M.
NEUROMUSCULAR DISORDERS, 2019, 29 (02) : 157 - 158
[26] Pharmacological prospects in the treatment of Duchenne muscular dystrophy
Ruegg, Urs T.
CURRENT OPINION IN NEUROLOGY, 2013, 26 (05) : 577 - 584
[27] Development of PPMO for the Treatment of Duchenne Muscular Dystrophy
Passini, Marco A.
Gan, Li
Wood, Jenna A.
Yao, Monica
Estrella, Nelsa L.
Treleaven, Chris M.
Wentworth, Bruce M.
Charleston, Jay S.
Rutkowski, Joseph V.
Hanson, Gunnar J.
NEUROLOGY, 2018, 90
[28] Duchenne muscular dystrophy: diagnosis and perspective of treatment
Angelini, Corrado
JOURNAL OF TRANSLATIONAL GENETICS AND GENOMICS, 2024, 8 (02) : 244 - 248
[29] Eteplirsen for the Treatment of Duchenne Muscular Dystrophy (DMD)
Charleston, J. S.
Schnell, F. J.
Dworzak, J.
Donoghue, C.
Lynch, J.
Lewis, S.
Chen, L.
Rodino-Klapac, L. R.
Sahenk, Z.
Voss, J.
DeAlwis, U.
Frank, D. E.
Eliopoulos, H.
Mendell, J. R.
NEUROLOGY, 2017, 88
[30] Regarding "Eteplirsen for the treatment of Duchenne muscular dystrophy"
Unger, Ellis F.
Califf, Robert M.
ANNALS OF NEUROLOGY, 2017, 81 (01) : 162 - 164

← 1 2 3 4 5 →